
|Videos|May 6, 2021
A look at real-world trial data replication outcomes from IRIS Registry data
Author(s)David Hutton, OT Staff Reports
Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.
Advertisement
Theodore Leng, MD, medical advisor at Verana Health and director of clinical translational research, Byers Eye Institute, Stanford University School of Medicine, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," in which the first replications using real-world data of a phase 3 trial was utilized, during the virtual 2021 ARVO meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Revakinagene taroretcel-lwey for MacTel: Charles Wykoff, MD, PhD, on a year of real-world experience
2
Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis
3
Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control
4
Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year
5






















